Dementia expert Dr. Jason Karlawish told CNBC he was skeptical about the Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm. “Another study is needed to see if this drug is actually effective. Unfortunately, the FDA has approved the drug for marketing, although they also want another study,” said the co-director of the Penn …
Continue reading “Dementia skilled says proof was “inadequate” for approval”